日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

BCAR3 Hypomethylation as a Potential Diagnostic Marker for Thyroid Cancer and Its Mechanism via Promoting EMT and AKT/mTOR Pathway.

BCAR3 低甲基化作为甲状腺癌的潜在诊断标志物及其通过促进 EMT 和 AKT/mTOR 通路发挥作用的机制。

期刊:Cancers
影响因子:4.4
doi:10.3390/cancers18020267
Yu Wenkang, Mao Yizhu, Yin Yifei, Yang Jiacheng, Zhang Yi, Huang Xuandong, Zhang Yifen, Jiang Chenxia, Yang Rongxi
甲状腺癌
信号转导
AKT
MTOR
BCAR3
mTOR
发表日期：2026
文献求助 收藏

FABP3 methylation as a novel biomarker for the differentiation and classification of benign and malignant thyroid nodules

FABP3甲基化作为鉴别和分类良恶性甲状腺结节的新型生物标志物

期刊:Frontiers in Endocrinology
影响因子:4.6
doi:10.3389/fendo.2025.1630001
Huang, Haixia; Yin, Yifei; Mao, Yizhu; Li, Hong; Li, Junjie; Li, Mengxia; Zhang, Yi; Huang, Xuandong; Zhang, Yifen; Jiang, Chenxia; Yang, Rongxi
表观遗传
免疫/内分泌
发表日期：2025
文献求助 收藏

RASGEF1C methylation for the distinguishment and classification of benign and malignant thyroid tumors

RASGEF1C甲基化在鉴别和分类甲状腺良恶性肿瘤中的应用

期刊:Clinical Epigenetics
影响因子:4.4
doi:10.1186/s13148-025-01931-y
Yu, Wenkang; Yin, Yifei; Li, Mengxia; Huang, Haixia; Li, Junjie; Zhang, Yi; Zhu, Lun; Zhang, Yifen; Huang, Xuandong; Jiang, Chenxia; Yang, Rongxi
肿瘤
表观遗传
肿瘤免疫
RAS
免疫/内分泌
发表日期：2025
文献求助 收藏

SERPINA1 methylation as a novel diagnostic marker for early-stage papillary thyroid carcinoma via MAPK6-AKT/mTOR pathway.

SERPINA1 甲基化通过 MAPK6-AKT/mTOR 通路成为早期乳头状甲状腺癌的新型诊断标志物

期刊:Clinical Epigenetics
影响因子:4.4
doi:10.1186/s13148-025-01891-3
Li Junjie, Huang Haixia, Yin Yifei, Mao Yizhu, Li Mengxia, Li Hong, Jiang Chenxia, Yang Rongxi
肿瘤
mTOR
肿瘤免疫
发表日期：2025
文献求助 收藏

Peripheral blood-based S100P hypomethylation as a biomarker for the early-stage non-small cell lung cancer

外周血S100P低甲基化作为早期非小细胞肺癌的生物标志物

期刊:Epigenomics
影响因子:2.6
doi:10.1080/17501911.2025.2604020
Li, Junjie; Li, Wenli; Qiao, Rong; Zhang, Jie; Han, Baohui; Gu, Wanjian; Yang, Rongxi
肺癌
肿瘤
表观遗传
肿瘤免疫
细胞生物学
发表日期：2025
文献求助 收藏

The association between blood-based HYAL2 methylation and early-stage lung cancer: a case-control study

血液中HYAL2甲基化与早期肺癌的关联：一项病例对照研究

期刊:Lung Cancer Management
影响因子:0.7
doi:10.1080/17581966.2025.2477411
Qiao, Rong; Zhou, Xiajie; Li, Wenli; Zhong, Runbo; Wang, Jun; Song, Yakang; Zhang, Jing; Xu, Tian; Wang, Yue; Dai, Liping; Gu, Wanjian; Han, Baohui; Yang, Rongxi
肺癌
肿瘤
表观遗传
肿瘤免疫
发表日期：2025
文献求助 收藏

[Association between MLPH gene hypermethylation in peripheral blood and coronary heart disease]

[外周血中MLPH基因高甲基化与冠心病的相关性]

期刊:Nan fang yi ke da xue xue bao = Journal of Southern Medical University
影响因子:
doi:10.12122/j.issn.1673-4254.2025.09.06
Jin, Jialie; Wang, Fei; Zhu, Liya; Zhao, Xiaojing; Wang, Jinxin; Zhu, Chao; Yang, Rongxi
心血管
表观遗传
冠心病
发表日期：2025
文献求助 收藏

Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma

非小细胞肺癌中血液FOLR3甲基化异常和异质性凸显了其与肺鳞癌的密切关联。

期刊:Respiratory Research
影响因子:5
doi:10.1186/s12931-024-02691-8
Qu, Yunhui; Zhang, Xiuzhi; Qiao, Rong; Di, Feifei; Song, Yakang; Wang, Jun; Ji, Longtao; Zhang, Jie; Gu, Wanjian; Fang, Yifei; Han, Baohui; Yang, Rongxi; Dai, Liping; Ouyang, Songyun
肺癌
肿瘤
表观遗传
肿瘤免疫
细胞生物学
发表日期：2024
文献求助 收藏

Blood-based HYAL2 methylation as a potential marker for the preclinical detection of coronary heart disease and stroke

血液中HYAL2甲基化作为冠心病和卒中临床前检测的潜在标志物

期刊:Clinical Epigenetics
影响因子:4.4
doi:10.1186/s13148-024-01742-7
Bi, Lanfei; Jin, Jialie; Fan, Yao; Liu, Yu; Xu, Haifeng; Li, Mengxia; Chen, Changying; Shen, Chong; Yang, Rongxi
表观遗传
心血管
冠心病
发表日期：2024
文献求助 收藏

IL21R hypomethylation as a biomarker for distinguishing benign and malignant breast tumours

IL21R低甲基化作为区分良性和恶性乳腺肿瘤的生物标志物

期刊:Epigenetics
影响因子:3.2
doi:10.1080/15592294.2024.2352683
Zang, Zishan; Yin, Yifei; Liu, Chunlan; Zhu, Qiang; Huang, Xuandong; Li, Hong; Yang, Rongxi
肿瘤
表观遗传
IL2
肿瘤免疫
发表日期：2024
文献求助 收藏